Upcoming Special Dividend at NovaBay Pharmaceuticals and Announcement of the 2025 Annual Meeting Highlighted by Company
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) has announced a one-time special cash dividend of $0.80 per share for its common stock, payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025.
In light of the special dividend, NYSE American has advised the Company that its common stock will trade with 'due bills' from September 15, 2025 to September 29, 2025. This means that a seller of common stock during this period is obligated to deliver the special dividend payable on such common stock to the buyer. Stockholders who sell their common stock during the Dividend Right Period will not be entitled to receive the special dividend.
The Company filed a preliminary proxy statement for the 2025 Annual Meeting with the Securities and Exchange Commission on September 10, 2025. The Company plans to file a definitive proxy statement as soon as reasonably possible. The definitive proxy statement, the Company's annual report, and a proxy card will be mailed to each stockholder entitled to vote at the 2025 Annual Meeting.
Other information regarding the participants in the proxy solicitation and a description of their interests will be contained in the definitive proxy statement for the 2025 Annual Meeting and other relevant materials to be filed with the SEC with respect to the 2025 Annual Meeting. A list of the names of the directors and executive officers of the Company and information regarding their interests in the Investment Transaction is contained in the Preliminary Proxy Statement and will be contained in the definitive proxy statement for the 2025 Annual Meeting.
Stockholders are urged to read the definitive proxy statement and any other relevant documents when they become available. The information provided on the Company's website is not part of this communication. Stockholders can obtain the Preliminary Proxy Statement, definitive proxy statement, and other relevant documents for free from the SEC's website, the Company's investor relations website, or by writing to NovaBay Pharmaceuticals.
NovaBay Pharmaceuticals, Inc. has announced a virtual-only format for their annual shareholders meeting in October 2025 to ensure shareholder participation. The Company plans to hold its 2025 Annual Meeting of Stockholders on October 16, 2025.
The Company and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies from the Company's stockholders in connection with the Investment Transaction. Justin Hall, the General Counsel and Vice President of Business Development for NovaBay Pharmaceuticals, can be contacted at [email protected] for further information.
Please note that the forward-looking statements in this press release are subject to risks and uncertainties.
For more information about NovaBay Pharmaceuticals, please visit www.novabay.com.
Read also:
- Strategizing the Integration of Digital Menus as a Core Element in Business Operations
- Financial Actions of BlockDAG Following Inter and Borussia Agreements: Anticipating Future Steps
- International powers, including France, Germany, and the UK, advocate for the reinstatement of sanctions against Iran.
- Companies urged to combat employee resignation crisis, as per findings from the Addeco Group
